Servier's sevasemten fails first major trial in Becker muscular dystrophy

Servier, the French pharmaceutical company, has disclosed that sevasemten — a cardiac myosin inhibitor originally developed by Edgewise Therapeutics — has failed its first major clinical test in Becker muscular dystrophy (BMD). STAT News reports the result as a surprise setback.

BMD is caused by mutations in the DMD gene that result in a truncated but partially functional form of the dystrophin protein, distinguishing it from the more severe Duchenne muscular dystrophy. The condition typically manifests in adolescence or early adulthood with progressive skeletal and cardiac muscle weakness, and there are no approved disease-modifying treatments specifically for BMD. The myosin inhibitor class — which includes mavacamten, approved for hypertrophic cardiomyopathy — was being explored in BMD based on evidence that reducing excessive myosin activation might protect muscle fibres from damage.

Servier acquired sevasemten as part of a deal with Edgewise Therapeutics valued at approximately $1.55 billion. The nature and endpoints of the trial that failed have not been fully detailed in the feed item, and further results may be presented at a scientific meeting.

The setback is relevant to the rare disease field more broadly, as BMD represents a genetically defined patient population for whom no effective pharmacological option exists. The result also illustrates the persistent difficulty of translating myosin-targeting biology from cardiac to skeletal muscle contexts. No specific mechanistic interpretation is available from the feed item alone.